¶ PPI
¶ Definition
Proton pump inhibitors (PPIs) are medications that irreversibly block the H+/K+-ATPase enzyme in gastric parietal cells, suppressing stomach acid production and raising gastric pH from the evolutionarily normal 1.5 to 4-5. PPIs are among the most prescribed drugs globally but have significant long-term consequences.
¶ Mechanism
PPIs covalently bind to and inactivate the H+/K+-ATPase proton pump in parietal cells, preventing H+ secretion into the stomach lumen. This raises pH from 1.5 (normal human stomach) to 4-5, dramatically reducing the stomach's antimicrobial barrier function. At pH 4-5, bacteria that would normally be killed (including H. pylori, pathogenic E. coli, Clostridium) can survive and colonize. The loss of acidity also impairs protein digestion (pepsinogen activation requires pH 
), reduces mineral absorption (calcium, magnesium, iron, B12), and allows bacterial overgrowth in the small intestine (SIBO). PPIs shift the gastric and intestinal microbiome toward dysbiosis.
¶ Clinical Significance
PPI use is devastating to gut health and systemic immunity. By raising stomach pH, PPIs eliminate the human evolutionary adaptation for carnivorous/scavenger diet (pH 1.5). This increases risk of SIBO, C. difficile infection, pneumonia, osteoporosis (reduced calcium absorption), B12 deficiency, hypomagnesemia, and dysbiosis. Long-term PPI use is associated with increased risk of gastric cancer, kidney disease, dementia, and all-cause mortality. Patients on PPIs should be supported with betaine HCl, digestive enzymes, and gradual weaning when appropriate.
¶ Key Facts
- Raise stomach pH from 1.5 to 4-5
- Eliminate the antimicrobial barrier function of gastric acid
- Increase risk of SIBO, C. difficile, pneumonia, and enteric infections
- Impair absorption of calcium, magnesium, iron, and vitamin B12
- Associated with increased fracture risk (osteoporosis) from reduced calcium absorption
- Shift gastric and intestinal microbiome toward dysbiosis
- Long-term use linked to kidney disease, dementia, and increased mortality
- Often inappropriately prescribed for non-specific dyspepsia
¶ Connections
- stomach acid — PPIs suppress stomach acid production to raise pH to 4-5
- pH regulation — PPIs disrupt normal gastric pH homeostasis
- H. pylori — PPI use can allow H. pylori overgrowth despite treating H. pylori-related ulcers
- parietal cells — PPIs irreversibly bind to H+/K+-ATPase in parietal cells
- SIBO — PPI use is a major risk factor for small intestinal bacterial overgrowth
- dysbiosis — PPIs shift gastric and intestinal microbiome toward dysbiosis
- betaine HCl — betaine HCl can restore stomach acidity in patients with PPI-induced hypochlorhydria
- hypochlorhydria — PPIs induce iatrogenic hypochlorhydria
- calcium absorption — PPIs reduce calcium absorption leading to osteoporosis risk
- vitamin B12 — PPIs impair B12 absorption by reducing acid needed to cleave B12 from food proteins
- magnesium — PPIs cause hypomagnesemia through reduced absorption
- iron — PPIs reduce iron absorption by preventing ferric to ferrous conversion
- pepsin — PPIs prevent pepsinogen activation to pepsin (requires pH )
- protein digestion — PPIs impair protein digestion by reducing pepsin activation
- gut microbiome — PPIs profoundly alter gut microbiome composition
- Clostridium difficile — PPI use increases C. difficile infection risk 2-3 fold
- pneumonia — PPIs increase pneumonia risk through bacterial aspiration from stomach
- kidney disease — long-term PPI use associated with chronic kidney disease
- dementia — observational studies link PPI use to increased dementia risk
- all-cause mortality — long-term PPI use associated with increased all-cause mortality
¶ Module References
- Module 6